Dr. med. Thomas Ruhstaller
Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors
Templeton A, Thürlimann B, Baumann M, Mark M, Stoll S, Schwizer M, Dietrich D, Ruhstaller T. Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors. BMC cancer 2013; 13:153.
Mar 25, 2013Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors
Mar 25, 2013BMC cancer 2013; 13:153
Templeton Arnoud J, Thürlimann Beat, Baumann Michael, Mark Michael, Stoll Sarah, Schwizer Madeleine, Dietrich Daniel, Ruhstaller Thomas
Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer
Lutz M, Oyama T, Roth A, Rueschoff J, Ruhstaller T, Seruca R, Stahl M, Sterzing F, van Cutsem E, van der Gaast A, van Lanschot J, Ychou M, Moehler M, Mariette C, Lordick F, Zalcberg J, Ducreux M, Ajani J, Allum W, Aust D, Bang Y, Cascinu S, Hölscher A, Jankowski J, Jansen E, Kisslich R, Otto F. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer 2012; 48:2941-53.
Aug 23, 2012Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer
Aug 23, 2012Eur J Cancer 2012; 48:2941-53
Lutz Manfred P, Oyama Tsuneo, Roth Arnaud, Rueschoff Josef, Ruhstaller Thomas, Seruca Raquel, Stahl Michael, Sterzing Florian, van Cutsem Eric, van der Gaast Ate, van Lanschot Jan, Ychou Marc, Moehler Markus, Mariette Christophe, Lordick Florian, Zalcberg John R, Ducreux Michel, Ajani Jaffer A, Allum William, Aust Daniela, Bang Yung-Jue, Cascinu Stefano, Hölscher Arnulf, Jankowski Janusz, Jansen Edwin P M, Kisslich Ralf, Otto Florian
Cervical and vaginal cancer in a woman with chronic graft-versus-host disease
Bolla D, Ruhstaller T, Diener P, Winder F, Hornung R. Cervical and vaginal cancer in a woman with chronic graft-versus-host disease. Int J Gynecol Obstet 2011; 114:159-160.
Jun 12, 2011Cervical and vaginal cancer in a woman with chronic graft-versus-host disease
Jun 12, 2011Int J Gynecol Obstet 2011; 114:159-160
Bolla Daniele, Ruhstaller Thomas, Diener Pierre-André, Winder Franziska, Hornung René
Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03)
Köberle D, Thürlimann B, Pilop C, Crowe S, Öhlschlegel C, von Moos R, Zaman K, Pagani O, Jost L, Ruhstaller T, Swiss Group for Clinical Cancer Research (SAKK). Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03). Endocr Relat Cancer 2011; 18:257-64.
Mar 9, 2011Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03)
Mar 9, 2011Endocr Relat Cancer 2011; 18:257-64
Köberle Dieter, Thürlimann Beat, Pilop C, Crowe S, Öhlschlegel Christian, von Moos R, Zaman K, Pagani O, Jost L, Ruhstaller Thomas, Swiss Group for Clinical Cancer Research (SAKK)
Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)
Ruhstaller T, Brauchli P, Inauen R, Widmer L, Mingrone W, Gautschi O, Rauch D, Schneider P, Montemurro M, Moosmann P, von Moos R, Kranzbuehler H, Dietrich D, Pless M, Hess V. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). J Clin Oncol 2011; 29:626-31.
Jan 4, 2011Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)
Jan 4, 2011J Clin Oncol 2011; 29:626-31
Ruhstaller Thomas, Brauchli Peter, Inauen Roman, Widmer Lucas, Mingrone Walter, Gautschi Oliver, Rauch Daniel, Schneider Paul M, Montemurro Michael, Moosmann Peter, von Moos Roger, Kranzbuehler Helmut, Dietrich Daniel, Pless Miklos, Hess Viviane
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
Rochlitz C, Zaman K, Mayer M, Cliffe B, Herrmann R, Mannhart-Harms M, Muller A, Rauch D, Winterhalder R, von Moos R, Schonenberger A, Fehr M, Bühlmann M, Suter T, Huober J, Spirig C, Lerch S, Ruhstaller T, Swiss Group for Clinical Cancer Research (SAKK). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Ann Oncol 2010; 22:80-5.
Jul 1, 2010Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
Jul 1, 2010Ann Oncol 2010; 22:80-5
Rochlitz C, Zaman K, Mayer M, Cliffe B, Herrmann R, Mannhart-Harms M, Muller A, Rauch D, Winterhalder R, von Moos R, Schonenberger A, Fehr M, Bühlmann M, Suter T, Huober Jens, Spirig C, Lerch S, Ruhstaller Thomas, Swiss Group for Clinical Cancer Research (SAKK)
Brustzentrum Kantonsspital St. Gallen – von der Multidisziplinarität zur patientinnenzentrierten interdisziplinären Betriebsorganisation
Baumann M, Thürlimann B, Ruhstaller T. Brustzentrum Kantonsspital St. Gallen – von der Multidisziplinarität zur patientinnenzentrierten interdisziplinären Betriebsorganisation. Breast Care 2010; 5:188-191.
Jun 8, 2010Brustzentrum Kantonsspital St. Gallen – von der Multidisziplinarität zur patientinnenzentrierten interdisziplinären Betriebsorganisation
Jun 8, 2010Breast Care 2010; 5:188-191
Baumann Michael, Thürlimann Beat, Ruhstaller Thomas
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study
Rao S, Beadman C, Kurek R, Archer C, Wilke H, Valladares-Ayerbes M, Ruhstaller T, Gilligan D, Sumpter K, Cunningham D, Starling N, Oates J. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol 2010; 21:2213-9.
May 23, 2010Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study
May 23, 2010Ann Oncol 2010; 21:2213-9
Rao S, Beadman C, Kurek R, Archer C, Wilke H, Valladares-Ayerbes M, Ruhstaller Thomas, Gilligan D, Sumpter K, Cunningham D, Starling N, Oates J
Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02)
Jost C, Meyenberger C, Brauchli P, Bertschinger P, Frossard J, Knuchel J, Werth B, Metzger U, Bauerfeind P, Schuller J, Binek J, Ruhstaller T. Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02). Gastrointest Endosc 2010; 71:1114-21.
Mar 20, 2010Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02)
Mar 20, 2010Gastrointest Endosc 2010; 71:1114-21
Jost Christian, Meyenberger Christa, Brauchli Peter, Bertschinger Philipp, Frossard Jean-Louis, Knuchel Juerg, Werth Baseli, Metzger Urs, Bauerfeind Peter, Schuller Jan C, Binek Janek, Ruhstaller Thomas
Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02)
Ruhstaller T, Köberle D, von Briel C, Lombriser N, Lohri A, Pederiva S, von Moos R, Thierstein S, Borner M, Schuller J, Ribi K, Templeton A, Popescu R. Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02). Onkologie 2010; 33:222-8.
Jan 1, 2010Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02)
Jan 1, 2010Onkologie 2010; 33:222-8
Ruhstaller Thomas, Köberle Dieter, von Briel Christian, Lombriser Norbert, Lohri Andreas, Pederiva Stefanie, von Moos Roger, Thierstein Sandra, Borner Markus, Schuller Jan C, Ribi Karin, Templeton Arnoud, Popescu Razvan
Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03)
von Moos R, Lanz D, Simcock M, Köberle D, Cathomas R, Uhlmann C, Widmer L, Ruhstaller T, Roth A, Popescu R. Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03). Onkologie 2010; 33:295-9.
Jan 1, 2010Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03)
Jan 1, 2010Onkologie 2010; 33:295-9
von Moos Roger, Lanz Doris, Simcock Mathew, Köberle Dieter, Cathomas Richard, Uhlmann Catrina, Widmer Lucas, Ruhstaller Thomas, Roth Arnaud, Popescu Razvan
Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer
Ruhstaller T, Köberle D, von Briel C, Lombriser N, Lohri A, Pederiva S, von Moos R, Thierstein S, Borner M, Schuller J, Ribi K, Templeton A, Popescu R. Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer. Onkologie 2010; 33:222-228.
Jan 1, 2010Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer
Jan 1, 2010Onkologie 2010; 33:222-228
Ruhstaller Thomas, Köberle Dieter, von Briel C, Lombriser N, Lohri A, Pederiva S, von Moos Roger, Thierstein S, Borner M, Schuller J C, Ribi K, Templeton Arnoud, Popescu R
Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02)
Klaeser B, Ruhstaller T, von Moos R, Albrecht S, Caspar C, Pestalozzi B, Zünd M, Brauchli P, Cescato-Wenger C, Hany T, Balmer-Majno S, Widmer L, Köberle D, Schuller J, Nitzsche E, Lange J. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02). Onkologie 2009; 32:724-30.
Dec 1, 2009Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02)
Dec 1, 2009Onkologie 2009; 32:724-30
Klaeser Bernd, Ruhstaller Thomas, von Moos Roger, Albrecht Susanne, Caspar Clemens, Pestalozzi Bernhard C, Zünd Michael, Brauchli Peter, Cescato-Wenger Corinne, Hany Thomas, Balmer-Majno Sabine, Widmer Lucas, Köberle Dieter, Schuller Jan C, Nitzsche Egbert, Lange Jochen
Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
Cathomas R, Köberle D, Ruhstaller T, Mayer G, Räss A, Mey U, von Moos R. Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2009
Sep 12, 2009Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
Sep 12, 2009Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2009
Cathomas Richard, Köberle Dieter, Ruhstaller Thomas, Mayer Gisela, Räss Andrea, Mey Ulrich, von Moos Roger
Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)
Ruhstaller T, Popescu R, Bodis S, Schnider A, Terraciano L, Köberle D, Balmermajno S, Pestalozzi B, Borner M, von Moos R, Mingrone W, Hess V, Roth A, Schuller J, Widmer L, Swiss Group for Clinical Cancer Research (SAKK). Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009; 20:1522-8.
Sep 1, 2009Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)
Sep 1, 2009Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009; 20:1522-8
Ruhstaller Thomas, Popescu R, Bodis S, Schnider A, Terraciano L, Köberle Dieter, Balmermajno S, Pestalozzi B C, Borner M, von Moos R, Mingrone W, Hess V, Roth A, Schuller J C, Widmer L, Swiss Group for Clinical Cancer Research (SAKK)
Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?
Ribi K, Pestalozzi B, Lombriser N, Borner M, von Moos R, Moosmann P, Hess V, Roth A, Honegger H, Schuller J, Köberle D, Ruhstaller T. Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2009; 17:1109-1116.
Feb 7, 2009Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?
Feb 7, 2009Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2009; 17:1109-1116
Ribi Karin, Pestalozzi Bernhard, Lombriser Norbert, Borner Markus, von Moos Roger, Moosmann Peter, Hess Viviane, Roth Arnaud, Honegger Hanspeter, Schuller Jan C, Köberle Dieter, Ruhstaller Thomas
Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study
Ruhstaller T, Böhme C, Hess D, Hoefliger M, Mueller U, Köberle D, Spaeti B, Glaus A, Ribi K, Rufibach K, von Moos R, Thürlimann B. Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study. Oncology 2009; 76:142-8.
Jan 1, 2009Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study
Jan 1, 2009Oncology 2009; 76:142-8
Ruhstaller Thomas, Böhme Christel, Hess Dagmar, Hoefliger Markus, Mueller Urs, Köberle Dieter, Spaeti Bruno, Glaus Agnes, Ribi Karin, Rufibach Kaspar, von Moos Roger, Thürlimann Beat
Adenokarzinome des Oesophagus und des Magens: Vergleichende Epidemiologie mit markanten Unterschieden
Inauen R, Ruhstaller T. Adenokarzinome des Oesophagus und des Magens: Vergleichende Epidemiologie mit markanten Unterschieden. Onkologie 2009; 1:6-7.
Jan 1, 2009Adenokarzinome des Oesophagus und des Magens: Vergleichende Epidemiologie mit markanten Unterschieden
Jan 1, 2009Onkologie 2009; 1:6-7
Inauen Roman, Ruhstaller Thomas
Magen- und gastroösophageales Uebergangskarzinom: Diagnostik und Therapieoptionen des frühen bis metastasierten Tumorstadiums
Inauen R, Ruhstaller T. Magen- und gastroösophageales Uebergangskarzinom: Diagnostik und Therapieoptionen des frühen bis metastasierten Tumorstadiums. Onkologie 2009; 1:8-13.
Jan 1, 2009Magen- und gastroösophageales Uebergangskarzinom: Diagnostik und Therapieoptionen des frühen bis metastasierten Tumorstadiums
Jan 1, 2009Onkologie 2009; 1:8-13
Inauen Roman, Ruhstaller Thomas
Radiation recall dermatitis with soft tissue necrosis following pemetrexed therapy: a case report
Spirig C, Omlin A, D'Addario G, Loske K, Esenwein P, Geismar J, Ruhstaller T. Radiation recall dermatitis with soft tissue necrosis following pemetrexed therapy: a case report. J Med Case Reports 2009; 3:93.
Jan 1, 2009Radiation recall dermatitis with soft tissue necrosis following pemetrexed therapy: a case report
Jan 1, 2009J Med Case Reports 2009; 3:93
Spirig Christian, Omlin Aurelius, D'Addario Giannicola, Loske Klaus-Dieter, Esenwein Philipp, Geismar Jan Henning, Ruhstaller Thomas